Search

Your search keyword '"Gillette, Michael A."' showing total 342 results

Search Constraints

Start Over You searched for: Author "Gillette, Michael A." Remove constraint Author: "Gillette, Michael A."
342 results on '"Gillette, Michael A."'

Search Results

1. Comprehensive proteogenomic characterization of rare kidney tumors

2. Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues

3. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma

4. Pan-cancer proteogenomics characterization of tumor immunity

5. Deep learning integrates histopathology and proteogenomics at a pan-cancer level

6. Proteogenomic insights suggest druggable pathways in endometrial carcinoma

7. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

8. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation

9. Pan-cancer proteogenomics connects oncogenic drivers to functional states

10. Proteogenomic data and resources for pan-cancer analysis

13. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups

14. Pan-cancer proteogenomics characterization of tumor immunity

15. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

16. Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia

19. Deep learning integrates histopathology and proteogenomics at a pan-cancer level

20. OA-35 High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression

21. Proteogenomic insights suggest druggable pathways in endometrial carcinoma

22. Pan-cancer proteogenomics connects oncogenic drivers to functional states

23. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

24. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation

25. Proteogenomic data and resources for pan-cancer analysis

27. Data from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

28. Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

29. Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

30. Microscaled proteogenomic methods for precision oncology

32. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry

33. Supplementary File 5 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

34. Supplementary File 1 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

35. Supplementary File 2 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

36. Extended Methods from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

37. Supplementary File 3 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

38. Supplementary Figures from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

39. Supplementary tables 1 and 2 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

40. Data from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

41. Supplementary File 4 from Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

42. Abstract P5-02-36: Proteogenomic profiling of fresh frozen core biopsies from CALGB 40601

43. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

44. High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

45. Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

47. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

48. Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial

Catalog

Books, media, physical & digital resources